Alkermes

ALKS

Market cap $5.27B

DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept.

— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia — — Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 — DUBLIN , Sept.

Alkermes plc (NASDAQ:ALKS ) World Sleep Congress 2025 Conference September 8, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Craig Hopkinson - Executive VP of Research & Development and Chief Medical Officer Marcus Yountz - Vice President of Clinical Development Conference Call Participants Giuseppe Plazzi Akash Tewari - Jefferies LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Ami Fadia - Needham & Company, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Marc Goodman - Leerink Partners LLC, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Jason Gerberry - BofA Securities, Research Division Luke Herrmann - Robert W.

– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition  – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m.

Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with progress around revenue growth from its product portfolio and some pipeline progress. Analyst commentary is positive, and Alkermes has a rock-solid balance sheet with over $1 billion in net cash and no long-term debt.

ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.

Alkermes plc (NASDAQ:ALKS ) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.

The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.